Eliminating the guess work in ablation therapy

Real time Predictive visualization of true ablation damage 

Real-time ablation. Visualized.

The world’s first and only image analysis system that predicts and visualizes the 24-hour post-treatment ablation morphology in real-time

Allowing physicians to see where they have previously been blind

BioTrace™ interfaces with commercial ultrasound imaging systems to track the tissue’s unique “biological signature” when responding to heat during thermal ablation. This signature is used to predict and visualize the post 24-hour thermal effect in real-time, optimizing the surgeon’s level of control and accuracy during the procedure, to minimize healthy tissue damage and maximize target tissue ablation.

A comprehensive all-around system

An A to Z Solution, BioTrace™ affects and improves all stages of patient care, from PSM, through planning & simulation to real-time lesion imaging & efficacy analysis

 

Pre-interventional Patient Specific Modeling

Planning & Validation Of Manufacturers’ Protocols

Real-Time Visual Monitoring & Control Of Tissue Destruction

Real-Time Efficacy Analysis Of Post-Treatment Tissue Damage

Providing vision. Optimizing results.

A must have system for optimal ablation

Reduced recurrence rates

Maximize efficacy and minimize leftover pathologies

Increased safety

Prevent sever injuries due to overtreatment

Cost effective

No hardware necessary

Quick & easy to adopt

No change to existing surgical procedures

Case Studies

One real-time image is better than a thousand simulations

  • CASE 01

    • 61 Year-Old Patient
    • RFA Ablation
    • Tumor Size 1.8 cm
    • Liver Segment #3
    • Ablation time: 3 min

    92%

    BioTrace™ accuracy

    compared with 24h post CECT

    CASE 01

    92%

    BioTrace™ accuracy

    compared with 24h post CECT

  • CASE 02

    • 58 Year-old Patient
    • RFA Ablation
    • Tumor Size 2.2 cm
    • Liver Segment #6
    • Ablation time: 2.4min

    91% BioTrace™ accuracy

    compared with 24h post CECT

    CASE 02

    91% BioTrace™ accuracy

    compared with 24h post CECT

  • CASE 03

    • 63 Year-old Patient
    • MW Ablation
    • Tumor Size 1.5 cm
    • Liver segment #4
    • Ablation time: 2min

    90% BioTrace™ accuracy

    compared with 24h post CECT

    CASE 03

    90% BioTrace™ accuracy

    compared with 24h post CECT

Transforming ablation treatments into guided precision therapies

Current Application

Oncology
Liver tumor ablation

Advancing thermal ablation into the first line treatment option for tumor removal

Pipeline

Cardiovascular

Transitioning from complicated guess-work into precise, real-time feedback dependent treatments

Pain management

Dramatically increase safety in high-risk nerve-ablation procedures

Team

Yossi Abu CEO
Yogev Zohar R&D Manager
Eran Naveh Software Manager
Gal Peretz AI Researcher
Talia Goshen Deputy General Manager
Assaf Bashkin Product Manager
Slava Shtilerman Software Eng.
Dudi Levi DevOps & R&D
INBAL AMITI Clinical Engineer

Board of Directors

Chairman of the Board

Mr. Arie Rosenfeld

Former President & CEO,

Scitex Corp

Director

MR. YOSSI ABU

Founder & CEO, TechsoMed

Director

Mr. Eiji KAKIUCHI

Chairman,

SCREEN Holdings

Director

Mr. Tamir Meiri

Senior Manager,
JJDC, Inc

Director

Mr. Fred Shane

Managing Partner,

Axil Capital

Director

Mr. David Hankin

CEO, AMIT-Technion

Partnerships

Investors

Partners

Clinical

Contact Us

Contact info

TechsoMed
Tel | +972-8-6198866
Email | info@techsomed.com
Meir Weisgal 2, Rehovot, Israel